HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Giuseppe Curigliano Selected Research

Trastuzumab (Herceptin)

12/2023Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
12/2023Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
10/2023Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
1/2023Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
1/2023Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
1/2023Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
1/2023Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.
9/2022An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low).
8/2022Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.
1/2022Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Giuseppe Curigliano Research Topics

Disease

238Neoplasms (Cancer)
12/2024 - 03/2003
221Breast Neoplasms (Breast Cancer)
05/2024 - 09/2002
43Triple Negative Breast Neoplasms
03/2024 - 01/2013
24Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 05/2002
20Disease Progression
05/2024 - 05/2007
15Neoplasm Metastasis (Metastasis)
11/2023 - 09/2002
11Melanoma (Melanoma, Malignant)
01/2024 - 08/2013
11Cardiotoxicity
09/2022 - 09/2010
10Microsatellite Instability
01/2022 - 01/2017
8Colorectal Neoplasms (Colorectal Cancer)
11/2023 - 04/2013
8COVID-19
01/2022 - 01/2020
8Prostatic Neoplasms (Prostate Cancer)
02/2021 - 05/2007
6Stomach Neoplasms (Stomach Cancer)
11/2023 - 09/2007
5Carcinogenesis
06/2023 - 12/2016
5Brain Neoplasms (Brain Tumor)
01/2023 - 11/2017
5Cardiovascular Diseases (Cardiovascular Disease)
01/2023 - 02/2013
5Lung Neoplasms (Lung Cancer)
03/2022 - 07/2003
5Carcinoma (Carcinomatosis)
01/2022 - 03/2005
5Heart Failure
01/2018 - 09/2010
4Circulating Neoplastic Cells
01/2024 - 10/2010
4Thyroid Neoplasms (Thyroid Cancer)
11/2023 - 01/2021
4Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
12/2022 - 03/2020
4Pain (Aches)
01/2018 - 09/2007
3Pathologic Complete Response
12/2023 - 03/2020
3Inflammatory Breast Neoplasms
11/2023 - 01/2018
3Interstitial Lung Diseases (Interstitial Lung Disease)
01/2023 - 12/2021
3Noninfiltrating Intraductal Carcinoma (DCIS)
01/2022 - 09/2017

Drug/Important Bio-Agent (IBA)

56Biomarkers (Surrogate Marker)IBA
05/2024 - 09/2007
54Hormones (Hormone)IBA
05/2024 - 10/2004
32Immune Checkpoint InhibitorsIBA
01/2024 - 03/2014
31Trastuzumab (Herceptin)FDA Link
12/2023 - 01/2006
27Immunoconjugates (Immunoconjugate)IBA
05/2024 - 01/2019
25Estrogen ReceptorsIBA
05/2024 - 10/2004
24human ERBB2 proteinIBA
12/2023 - 11/2013
20ErbB Receptors (EGF Receptor)IBA
02/2024 - 12/2004
16VaccinesIBA
01/2024 - 09/2007
14AntigensIBA
02/2024 - 10/2009
13Phenobarbital (Luminal)FDA Link
05/2024 - 10/2012
13trastuzumab deruxtecanIBA
05/2024 - 12/2021
13Progesterone Receptors (Progesterone Receptor)IBA
01/2021 - 06/2004
11Proteins (Proteins, Gene)FDA Link
02/2023 - 03/2003
9Poly(ADP-ribose) Polymerase InhibitorsIBA
03/2024 - 01/2020
9palbociclibIBA
02/2024 - 01/2019
9Biosimilar PharmaceuticalsIBA
01/2023 - 09/2014
9COVID-19 VaccinesIBA
01/2022 - 01/2021
9AnthracyclinesIBA
11/2021 - 06/2015
8AntibodiesIBA
01/2024 - 08/2013
8Monoclonal AntibodiesIBA
01/2023 - 09/2010
8Cisplatin (Platino)FDA LinkGeneric
01/2023 - 09/2004
8DNA (Deoxyribonucleic Acid)IBA
11/2022 - 03/2003
7Paclitaxel (Taxol)FDA LinkGeneric
02/2024 - 12/2006
7sacituzumab govitecanIBA
11/2023 - 01/2020
7Ado-Trastuzumab EmtansineIBA
11/2023 - 01/2018
7Cancer VaccinesIBA
01/2022 - 09/2007
7Tyrosine Kinase InhibitorsIBA
11/2021 - 09/2010
7Gefitinib (Iressa)FDA Link
01/2021 - 02/2005
6Circulating Tumor DNAIBA
02/2024 - 06/2014
6pembrolizumabIBA
10/2023 - 01/2019
6atezolizumabIBA
09/2023 - 01/2019
6AlpelisibIBA
01/2023 - 08/2018
6Neoplasm Antigens (Tumor Antigens)IBA
11/2015 - 12/2007
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2024 - 09/2012
5NivolumabIBA
01/2024 - 01/2020
5Cyclin-Dependent Kinase 4IBA
12/2023 - 11/2017
5pralsetinibIBA
11/2023 - 01/2021
5ribociclibIBA
09/2023 - 05/2017
5LigandsIBA
06/2023 - 02/2015
5PlatinumIBA
01/2023 - 03/2005
5tucatinibIBA
01/2023 - 01/2020
5Capecitabine (Xeloda)FDA Link
01/2023 - 06/2015
4Cyclin-Dependent Kinases (cdk Proteins)IBA
05/2024 - 05/2017
4Peptides (Polypeptides)IBA
05/2024 - 09/2007
4Methotrexate (Mexate)FDA LinkGeneric
01/2024 - 09/2002
4IpilimumabIBA
01/2024 - 08/2013
4Aromatase InhibitorsIBA
03/2023 - 10/2019
4B7-H1 AntigenIBA
01/2023 - 01/2019
4taxaneIBA
01/2023 - 03/2005
4CTLA-4 AntigenIBA
09/2022 - 11/2013
4pertuzumabIBA
08/2022 - 01/2018
3abemaciclibIBA
05/2024 - 01/2019
3Docetaxel (Taxotere)FDA Link
12/2023 - 01/2017
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2023 - 05/2007
3margetuximabIBA
10/2023 - 01/2021
3Phosphotransferases (Kinase)IBA
06/2023 - 05/2014
3Epidermal Growth Factor (EGF)IBA
03/2023 - 10/2012
3Transaminases (Aminotransferases)IBA
01/2023 - 03/2005
3Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
10/2021 - 11/2015

Therapy/Procedure

128Therapeutics
12/2024 - 06/2004
71Drug Therapy (Chemotherapy)
04/2024 - 05/2002
39Immunotherapy
01/2024 - 09/2007
17Neoadjuvant Therapy
02/2024 - 01/2013
15Precision Medicine
01/2023 - 01/2014
14Radiotherapy
02/2024 - 03/2004
13Adjuvant Chemotherapy
01/2024 - 01/2013
6Mastectomy (Mammectomy)
11/2023 - 03/2004
6Catheters
10/2009 - 11/2002
4Segmental Mastectomy (Lumpectomy)
12/2023 - 03/2004
4Breast Implants (Breast Implant)
12/2022 - 03/2020
4Aftercare (After-Treatment)
01/2022 - 12/2004
4Mammaplasty (Breast Reconstruction)
10/2015 - 08/2011